The tumor microenvironment as a determinant of drug response and resistance

Drug Resistance Updates

Volumn 2, Issue 5, 1999, Pages 285-288

  Dalton, William S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOKINE; FIBRONECTIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; VINBLASTINE;

APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL ADHESION; CELL CONTACT; CELL SURVIVAL; EXTRACELLULAR MATRIX; HUMAN; MYELOMA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0033208328     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0097     Document Type: Article

References (36)

1. Dalton W. S. Mechanisms of drug resistance in hematologic malignancies. Semin Hematol. 34:1997;3-8.
2. Durand R. E., Sutherland R. M. Effects of intercellular contact on repair of radiation damage. Exp Cell Res. 71:1972;75-80.
3. Kawano M., Hirano T., Matsuda T. Autocrine generation and requirement of BSF-2/L-6 for human multiple myelomas. Nature. 332:1988;83-85.
4. Klein B., Lu Z. Y., Bataille R. Interleukin-6 in human multiple myeloma. Blood. 85:1995;863-872.
5. Lichtenstein A., Tu Y., Fady C., Vescio R., Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 162:1995;248-255.
6. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
7. Chauhan D., Kharbanda S., Ogata A. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 89:1997;227-234.
8. Lotem J., Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor b1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood. 80:1992;1750-1757.
9. Puthier D., Bataille R., Barille S. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Blood. 88:1996;4659-4666.
10. Lichtenstein A., Tu Y., Fady C., Vescio R., Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 162:1995;248-255.
11. Shiao R. T., Miglietta L., Khera S. Y. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines. Leuk Lymphoma. 17:1995;485-494.
12. Hardin J., MacLeod S., Grigorieva I. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 84:1991;3063-3070.
13. Aoyama M., MacIsaac D., Bukowski R., Ganapathi M. Interleukin-6 differentially potentiates the antitumor effects of Taxol and vinblastine in U266 human myeloma cells. Clin Cancer Res. 4:1998;1039-1045.
14. Murakami M., Hibi M., Nakagawa N. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science. 260:1993;1808-1810.
15. Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp 130. Blood. 86:1995;1243-1254.
16. Chauhan D., Kharbanda S., Ogata A. Interleukin-6 inhibits FAS-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 89:1997;227-234.
17. Xu F. H., Sharma S., Gardner A. Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood. 92:1998;241-251.
18. Lutticken C., Wegenka U. M., Yuan J. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science. 263:1994;89-92.
19. Ihle J. N. STATs: signal transducers and activation of transcription. Cell. 84:1996;331-334.
20. Darnell K. E. Jr, Kerr I. M., Stark G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1994;1415-1421.
21. Tu Y., Renner S., Xu F. H. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res. 58:1998;256-262.
22. Schwarze M. M. K., Hawley R. G. Prevention of myeloma cell apoptosis by ectopic BCL-expression or interleukin-6 mediated upregulation of BCL-X-L. Cancer Res. 55:1995;2262-2265.
23. Catlett-Falcone R., Landowski T. H., Oshiro M. M. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human myeloma tumor cells. Immunity. 10:1999;105-115.
24. Teicher B. A., Herman T. S., Holden S. A. Tumor resistance to alkylating agents conferred by mehanisms operative only in vivo. Science. 247:1990;1457-1461.
25. St.Croix B., Florenes V. A., Rak J. W. Impact of the cyclin-dependent kinase inhibitor p27kip1 on resistance of tumor cells to anticancer agents. Nature Med. 2:1996;1204-1210.
26. Damiano J., Cress A., Hazlehurst L., Shtil A., Dalton W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 93:1999;1658-1667.
27. Meredeth J. E., Fazeli B., Schwartz M. A. the extracellular matrix as a cell survival factor. Mol Biol Cell. 4:1993;953-961.
28. Clark E. A., Brugge J. S. Integrins and signal transduction pathways: the road taken. Science. 268:1995;233-239.
29. Higashimoto I., Chihara J., Kakazu T., Kawabata M., Nakajima S., Osame M. Regulation of eosinophil cell death by adhesion to fibronectin. Int Arch Allergy Immunol. (Suppl 1) 111:1996;66-69.
30. Zhang Z., Vuori K., Reed JC Rouslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA. 92:1995;6161-6165.
31. Scott G., Cassidy L., Busacco A. Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanism. J Invest Dermatol. 108:1997;147-153.
32. Rozzo C., Chiesa C., Caridi G., Pagnan G., Ponzoni M. Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. Int J Cancer. 70:1997;688-698.
33. Hoyt D. G., Rusnak J. M., Mannix R. J., Modzelewski R. A., Johnson C. S., Lazo J. S. Integrin activation suppresses etopside-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res. 56:1996;4146-4149.
34. Kennedy S. G., Wagner A. J., Conzen S. D. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Devel. 11:1997;701-713.
35. Datta S. R., Dudek H., Tao X. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 92:1997;231-241.
36. Sethi T., Rintoul R., Moore S. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Med. 5:1999;662-668.